Donny Suh, MD
Pediatric Ophthalmology and Strabismus Specialist · Irvine, CANPI 1295727022
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,135 of the $13,865 with a category attached, or 65.9%. 16 manufacturers reported payments, led by Recordati_rare_diseases_inc. at 43.6% of the total. Among pediatric ophthalmology and strabismus specialist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $282.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Recordati_rare_diseases_inc.$6K
- Natus Medical Incorporated$5K
- Novartis$2K
- Dompe US, Inc.$369
- Amgen$207
- AstraZeneca$128
- plus $781 from 10 others
Across 2 payments — averaging $17,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Recordati_rare_diseases_inc.$35K
What the payments were for
- Consulting fees$2,84321%
- Speaking & faculty fees$9,13566%
- Food & beverage$1,85813%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Recordati_rare_diseases_inc. | 12 | $6,042 |
| Natus Medical Incorporated | 3 | $4,500 |
| Novartis | 2 | $1,838 |
| Dompe US, Inc. | 7 | $369 |
| Amgen(2 entities) | 3 | $207 |
| AstraZeneca | 1 | $128 |
| Spark Therapeutics, Inc. | 1 | $125 |
| Glaukos Corporation | 4 | $121 |
| Bausch & Lomb Americas Inc. | 1 | $112 |
| Santen Inc. | 1 | $110 |
| Genentech USA, Inc. | 1 | $106 |
| Leadiant Biosciences, Inc. | 3 | $77 |
| Sight Sciences, Inc. | 1 | $44 |
| Alcon | 1 | $33 |
| Travere Therapeutics, Inc. | 7 | $29 |
| Kedrion Biopharma, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CYSTADROPS$4,120
- PANHEMATIN$1,545
- Oxervate$226
- TEPEZZA$139
- KOSELUGO$128
- Carbaglu$120
- CYSTADANE$120
- XIIDRA$112
- Verkazia$110
How this compares
$13,865 in reported general payments places this provider in the 95th percentile of 28 pediatric ophthalmology and strabismus specialist providers in California.
See all pediatric ophthalmology and strabismus specialist providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 15 | $10,564 |
| RestasisCyclosporine | 13 | $9,057 |
| ErythromycinErythromycin Base | 20 | $151 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $112 | $10,56415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 pediatric ophthalmology and strabismus specialist providers in California.
Other pediatric ophthalmology and strabismus specialist in Irvine
- Charlotte GoreIrvine$380
- Stephen PrepasIrvine$269
- Scott LambertPalo Alto$20K
- Leila KhazaeniLoma Linda$9K
- Euna KooPalo Alto$6K
- Mark SilverbergSanta Barbara$5K
- Jennifer DunbarSan Bernardino$5K
- Shira RobbinsSan Diego$5K
- Mona FayadLos Angeles$3K
- Douglas FredrickDaly City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.